Can a new antibody calm severe eczema?
NCT ID NCT07103174
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This phase II trial is testing whether an experimental drug called MG-K10 can reduce the severity of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition. About 60 adults who have not responded well to topical treatments will receive either MG-K10 or a placebo via injection. The study measures how many participants achieve significant skin improvement after 24 weeks, as well as the drug's safety and how the body processes it.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MG-K10, an experimental humanized monoclonal antibody given by injection
- What this could lead to
- If successful, MG-K10 could offer a new treatment option for people with moderate-to-severe atopic dermatitis who do not get enough relief from topical creams.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. AD patients diagnosed in accordance with the consensus criteria of the American Academy of Dermatology (2014) had a history of AD or eczema diagnosis of ≥1 year 2. The patient's response to topical medication treatment is insufficient, or it is medically inappropriate to use topical medication for treatment 3. The subjects and their partners agreed to take effective contraceptive measures from signing the Informed Consent Form (ICF) until 6 months after the end of treatment, and had no plans for childbirth, sperm donation or egg donation Exclusion Criteria: 1. The subject currently has a diagnosis of other active skin diseases (such as psoriasis or lupus erythematosus) that may affect the evaluation of AD 2. Patients with eye diseases that the researchers judged as unsuitable for inclusion 3. Patients with malignant tumors within 5 years 4. There is evidence of active tuberculosis, or there has been evidence of active tuberculosis before and no appropriate documented treatment has been received 5. Confirm active parasitic infection 6. Those with active hepatitis, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb), or positive for hepatitis C virus (HCV) antibody, or positive for HIV antibody, or positive for (TP-Ab) 7. Women who are breastfeeding or pregnant, or women planning to become pregnant or breastfeed during the study period 8. Those who the researchers consider to have other circumstances that make them unsuitable to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hangzhou First People's Hospital
Zhejiang, 杭州, 310000, China
-
Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
Shanghai, Shanghai Municipality, 201203, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.